Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00396214 · ClinicalTrials.gov registry record · Phase 3
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 83
- Enrollment target
NCT00396214: Clinical Trial Phase 3 study, sponsored by Solvay Pharmaceuticals.
NCT00396214 is a Phase 3 study that was terminated before completion, run by Solvay Pharmaceuticals. The registered enrollment target is 83 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00396214, a Phase 3 study, was terminated before completion, sponsored by Solvay Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 83 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
Interventions
- DRUG Quetiapine
- DRUG Bifeprunox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Why NCT00396214 stopped before completion
NCT00396214 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Quetiapine is the first listed.
NCT00396214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00396214 about?
NCT00396214 is a clinical study titled "Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients". The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
What is the current status of trial NCT00396214?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 83 participants. The study started on 2007-04. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00396214?
The interventions under investigation include: Quetiapine (DRUG), Bifeprunox (DRUG).
Who is sponsoring clinical trial NCT00396214?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00396214's enrollment target sits among peer trials
83 1751st of 2000 higher than 249 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia